Viant Medical Bolts on Micro-molding Expertise

Viant Medical Inc. announced this week the addition of micro-molding capabilities to its portfolio of services for medical device OEMs with the acquisition of Knightsbridge Plastics.

Founded in 1982 and based in Fremont, CA, Knightsbridge Plastics is specialized in the design and production of precision injected-molded parts and micro-components for the medical device, biomedical, and technology sectors. The components are used in a range of medical devices, surgical procedures, and drug delivery systems.

Meeting demand for next-gen medical devices

Viant said the addition of Knightsbridge broadens its ability to produce highly specialized plastic injection-molded parts and intricate micro-components, which are increasingly in demand for next-generation medical devices and advanced drug-delivery systems. The acquisition also expands Viant’s global network of centers of excellence and strengthens its end-to-end solutions encompassing design and full-scale manufacturing of complex medical devices and components.

Previously named MedPlast LLC, the company rebranded in 2018 under the name Viant following the acquisition of Integer Holding Corp.’s Advanced Surgical and Orthopedics business. Prior to the name change, Viant entered the orthopedic market in 1970 and opened its first molding facility in 1979. Over the years it has expanded its manufacturing footprint with facilities in Europe, China, Mexico, Costa Rica, and throughout the United States. It offers an array of contract design and development, molding, extrusion, machining, and assembly services to global medical device OEMs.

Related:Viant Expands Medtech Manufacturing Capabilities Second Year in a Row

A reflection of Viant's commitment to support breakthrough technologies

Commenting on the acquisition of Knightsbridge Plastics, Viant CEO Alton Shader said: “We’re excited to incorporate some of the most innovative micro-molding technologies into our suite of services to produce complex components with unmatched precision and accuracy. This acquisition reflects our ongoing commitment to investing in advanced technologies and capabilities that support our customers by bringing breakthrough medical technologies to market.”